Latest news
AstraZeneca Drug Extends Survival in Advanced Gastric Cancer - MyChesCoMyChesCo · Sat, 08 Aug 2026 10:20:00 GMTFriday Five – Alnylam's quarter-cutting quarter, AstraZeneca's Claudin consolation, Capricor's statistical shock sequel…and more - FirstWord PHARMAFirstWord PHARMA · Fri, 31 Jul 2026 00:51:36 GMTKOL Views Preview: What to make of mixed survival data on AZ's Claudin18.2-targeting ADC in gastric cancer? - FirstWord PHARMAFirstWord PHARMA · Wed, 29 Jul 2026 03:15:19 GMTHong Kong-listed Keymed Biosciences’ gastric cancer drug meets late-stage trial goals - 1470 & 100.3 WMBD1470 & 100.3 WMBD · Tue, 28 Jul 2026 07:00:00 GMTAstraZeneca's Claudin 18.2-targeting ADC passes pivotal gastric cancer test - FirstWord PHARMAFirstWord PHARMA · Mon, 27 Jul 2026 20:25:00 GMTAstraZeneca’s rare disease drug misses main goal in late-stage trial - KELO-AMKELO-AM · Mon, 27 Jul 2026 07:26:07 GMTSonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers - AstraZenecaAstraZeneca · Mon, 27 Jul 2026 07:00:00 GMTAstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 07:00:00 GMT